- Home
- DAWN vs INVH Comparison
DAWN vs INVH Comparison
Compare DAWN & INVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- INVH
- Stock Information
- Founded
- DAWN 2018
- INVH 2012
- Country
- DAWN United States
- INVH United States
- Employees
- DAWN N/A
- INVH N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- INVH Real Estate
- Sector
- DAWN Health Care
- INVH Finance
- Exchange
- DAWN Nasdaq
- INVH Nasdaq
- Market Cap
- DAWN 624.8M
- INVH 18.5B
- IPO Year
- DAWN 2021
- INVH 2017
- Fundamental
- Price
- DAWN $7.18
- INVH $29.54
- Analyst Decision
- DAWN Strong Buy
- INVH Buy
- Analyst Count
- DAWN 7
- INVH 15
- Target Price
- DAWN $27.86
- INVH $36.70
- AVG Volume (30 Days)
- DAWN 922.7K
- INVH 3.5M
- Earning Date
- DAWN 10-29-2025
- INVH 10-29-2025
- Dividend Yield
- DAWN N/A
- INVH 3.91%
- EPS Growth
- DAWN N/A
- INVH 14.19
- EPS
- DAWN N/A
- INVH 0.89
- Revenue
- DAWN $187,638,000.00
- INVH $2,647,487,000.00
- Revenue This Year
- DAWN $12.56
- INVH $5.42
- Revenue Next Year
- DAWN $48.02
- INVH $3.66
- P/E Ratio
- DAWN N/A
- INVH $33.42
- Revenue Growth
- DAWN 2190.50
- INVH 5.09
- 52 Week Low
- DAWN $5.64
- INVH $29.37
- 52 Week High
- DAWN $16.76
- INVH $36.79
- Technical
- Relative Strength Index (RSI)
- DAWN 51.85
- INVH 39.11
- Support Level
- DAWN $6.90
- INVH $29.38
- Resistance Level
- DAWN $7.27
- INVH $30.02
- Average True Range (ATR)
- DAWN 0.26
- INVH 0.53
- MACD
- DAWN -0.06
- INVH -0.06
- Stochastic Oscillator
- DAWN 36.02
- INVH 8.21
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.